安罗替尼三线及以上治疗晚期非小细胞肺癌近期疗效和生命质量分析

摘要/Abstract

摘要：目的评价安罗替尼三线及以上治疗晚期非小细胞肺癌的近期疗效、安全性及对患者生命质量的影响。方法给予患者盐酸安罗替尼12 mg，1次/d，服用2周，休息1周，共3周为1周期，直至出现病情进展、不可耐受的不良事件。按照实体瘤疗效评价标准（RECIST）1.1评价疗效，常见不良事件评价标准（CTCAE）4.02评价不良事件，欧洲癌症治疗研究组织（EORTC）QLQC30和肺癌专项量表QLQLC13测定生命质量变化。结果入组27例患者，无完全缓解患者，部分缓解2例（7.4%），疾病稳定16例（59.3%），疾病进展9例（33.3%），客观缓解率为7.4%，疾病控制率为66.7%。QLQC30量表中躯体功能（76.00±10.55∶64.44±11.59）、情绪功能（81.67±8.71∶76.11±6.71）、总体健康状况（48.87±7.97∶40.56±12.49）评分较治疗前升高，差异有统计学意义（t=-4.516，P<0.001；t=-2.646，P=0.019；t=-3.872，P=0.002）。疲乏（50.37±8.95∶40.74±13.86）、恶心呕吐（26.54±16.18∶14.20±11.97）、食欲丧失［M(QR):33.33（33.33）∶33.33（33.33）］症状评分较治疗前升高（t=-2.476，P=0.027；t=-5.036，P＜0.001；Z=-2.923，P=0.003）；疼痛（28.88±14.23∶33.33±13.60）、呼吸困难［33.33（33.33）∶33.33（66.67）］评分较治疗前降低（t=3.674，P=0.003；Z=-3.266，P=0.001）。QLQLC13量表中咳嗽（24.44±19.12∶45.24±20.34）、气促［11.11（22.22）∶33.33（22.22）］、胸痛［0.00（33.33）∶33.33（33.33）］评分较前降低（t=4.000，P=0.001；Z=-4.125，P＜0.001；Z=-1.890，P=0.034）；口腔疼痛［0.00（33.33）∶0.00（0.00）］及手足刺痛［33.33（33.33）∶0.00（0.00）］评分较治疗前升高（Z=-2.000，P=0.046；Z=-2.264，P=0.024）。常见不良反应有高血压、疲劳、促甲状腺激素升高、蛋白尿、手足综合征、口腔黏膜炎、咯血等，主要为1～2级，对症处理后好转。结论安罗替尼三线及以上治疗晚期非小细胞肺癌疾病控制率较好，不良反应可耐受，可在一定程度上缓解临床症状，改善生命质量。

关键词:癌,非小细胞肺,受体,血管内皮生长因子,生活质量,安罗替尼

Abstract:ObjectiveTo evaluate the shortterm efficacy, safety and impact on the quality of life of anlotinib in thirdline and above treatment for advanced nonsmall cell lung cancer (NSCLC) patients. MethodsAll the patients received alotinib 12 mg/d. One cycle was defined as 2 weeks ontreatment followed by 1 week offtreatment until disease progression or treatment intolerance. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to assess tumor responses. Common Terminology Criteria for Adverse Events (CTCAE) 4.02 was used to assess the adverse events. The European Organization for Research on Treatment of Cancer (EORTC) QLQC30 and QLQLC13 were used to assess quality of life. ResultsAmong 27 patients in study, no complete response (CR) was found, 2 patients (7.4%) achieved partial response (PR), 16 patients (59.3%) achieved stable disease (SD), 9 patients (33.3%) achieved progressive disease (PD), objective response rate (ORR) was 7.4%, and disease control rate (DCR) was 66.7%. The scores of physical functioning (76.00±10.55 vs. 64.44±11.59), emotional functioning (81.67±8.71 vs. 76.11±6.71) and global health status (48.87±7.97 vs. 40.56±12.49) of the QLQC30 scale after treatment were higher than those before treatment, with statistically significant differences (t=-4.516, P<0.001; t=-2.646, P=0.019; t=-3.872, P=0.002). Fatigue (50.37±8.95 vs. 40.74±13.86), nausea and vomiting (26.54±16.18 vs. 14.20±11.97), loss of appetite ［M(QR): 33.33(33.33) vs. 33(33.33)］ were better than before (t=-2.476, P=0.027; t=-5.036, P＜0.001; Z=-2.923, P=0.003); pain (28.88±14.23 vs. 33.33±13.60) and dyspnea ［33.33(33.33) vs. 33.33(66.67)］ scores were lower than before (t=3.674, P=0.003; Z=-3.266, P=0.001). The scores of cough (24.44±19.12 vs. 45.24±20.34), shortness of breath ［11.11(22.22) vs. 33.33(22.22)］ and chest pain ［0.00(33.33) vs. 33.33(33.33)］ in the QLQLC13 scale after treatment were lower than those before treatment, with statistically significant differences (t=4.000, P=0.001; Z=-4.125, P＜0.001; Z=-1.890, P=0.034); the scores of sore mouth or tongue ［0.00(33.33) vs. 0.00(0.00)］ and hands and feet tingling ［33.33(33.33) vs. 0.00(0.00)］ were higher than before (Z=-2.000, P=0.046; Z=-2.264, P=0.024). Common adverse reactions included hypertension, fatigue, elevated thyroid stimulating hormone, proteinuria, handfoot syndrome, oral mucositis, hemoptysis, etc, mainly grade 12, and they were all improved after the treatments. ConclusionAnlotinib as a thirdline and further therapy is positive effected and well tolerated. It can alleviate the clinical symptoms and significantly improve the quality of life of NSCLC patients.

Key words:Carcinoma, non-small-cell lung,Receptors, vascular endothelial growth factor,Quality of life,Anlotinib

刘楠，吴秀伟，李烦繁，王年飞，张明军，孙彤，陈振东. 安罗替尼三线及以上治疗晚期非小细胞肺癌近期疗效和生命质量分析[J]. 国际肿瘤学杂志, 2019, 46(3): 147-152.

Liu Nan, Wu Xiuwei, Li Fanfan, Wang Nianfei, Zhang Mingjun, Sun Tong, Chen Zhendong. Shortterm clinical efficacy and analysis of quality of life of anlotinib in thirdline and above treatment for advanced nonsmall cell lung cancer[J]. Journal of International Oncology, 2019, 46(3): 147-152.

参考文献

［1］ Han B, Li K, Wang Q, et al. Effect of anlotinib as a thirdline or further treatment on overall survival of patients with advanced nonsmall cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial［J］. JAMA Oncol, 2018, 4(11): 15691575. DOI: 10.1001/jamaoncol.2018.3039. ［2］ Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45(2): 228247. DOI: 10.1016/j.ejca.2008.10.026. ［3］ Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQLC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life［J］. Eur J Cancer, 1994, 30A(5): 635642. ［4］ Shi J, Han B, Li K, et al. Subgroup analysis of elderly patients (pts) in ALTER0303: anlotinib hydrochloride as 3rdline and further line treatment in refractory advanced NSCLC pts from a randomized, doubleblind, placebocontrolled phase Ⅲ ALTER0303 trial［J］. J Clin Oncol, 2018, 36(15_suppl): e21181. DOI: 10.1200/JCO.2018.36.15_suppl.e21181. ［5］ Edeline J, Palmer D, Blanc JF, et al. mRECIST for systemic therapies: more evidence is required before recommendations can be made［J］. J Hepatol, 2017, 67(1): 195. DOI: 10.1016/j.jhep.2017.02.033. ［6］ Kamba T, McDonald DM. Mechanisms of adverse effects of antiVEGF therapy for cancer［J］. Br J Cancer, 2007, 96(12): 17881795. DOI: 10.1038/sj.bjc.6603813. ［7］ Han B, Li K, Wang Q, et al. Efficiency of anlotinib as 3rd line treatment in patients with different EGFR gene status, an exploratory subgroup analysis of ALTER0303 trial［J］. J Thorac Oncol, 2017, 12(11 suppl 2): S2275. DOI:https://doi.org/10.1016/j.jtho.2017.09.1632. ［8］ Cheng Y, Han B, Li K, et al. Subgroup analysis of histology in ALTER0303: anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts)［J］. J Clin Oncol, 2018, 36(15_suppl): 9080. DOI: 10.1200/JCO.2018.36.15_suppl.9080. ［9］ Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multitargeting tyrosine kinase inhibitor in clinical development［J］. J Hematol Oncol, 2018, 11(1): 120. DOI: 10.1186/s1304501806647.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏.人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华.电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	姚昌菊, 朱治法, 张梅.晚期腹膜后去分化脂肪肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 254-256.
[15]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.